faricimab
E238184
angiopoietin-2 inhibitor
biologic drug
bispecific monoclonal antibody
monoclonal antibody
ophthalmic drug
therapeutic antibody
vascular endothelial growth factor inhibitor
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
All labels observed (1)
| Label | Occurrences |
|---|---|
| faricimab canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2138581 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: faricimab Context triple: [Lucentis, isRelatedDrug, faricimab]
-
A.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
B.
Emgality
Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
E.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: faricimab Target entity description: Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
-
A.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
B.
Emgality
Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
E.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
angiopoietin-2 inhibitor
ⓘ
biologic drug ⓘ bispecific monoclonal antibody ⓘ monoclonal antibody ⓘ ophthalmic drug ⓘ therapeutic antibody ⓘ vascular endothelial growth factor inhibitor ⓘ |
| administeredBy | ophthalmologist ⓘ |
| adverseEffect |
conjunctival hemorrhage
ⓘ
eye pain ⓘ increased intraocular pressure ⓘ vitreous floaters ⓘ |
| approvalYear | 2022 ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| belongsToClass |
angiopoietin pathway inhibitors
ⓘ
anti-VEGF agents ⓘ |
| clinicalTrial |
LUCERNE
ⓘ
RHINE ⓘ TENAYA ⓘ YOSEMITE ⓘ |
| comparedWith | aflibercept ⓘ |
| contraindication |
active intraocular inflammation
ⓘ
ocular or periocular infection ⓘ |
| developedBy |
Genentech
ⓘ
Roche ⓘ |
| dosingInterval | up to every 16 weeks in some patients ⓘ |
| hasATCCode | S01LA07 ⓘ |
| hasTradeName | Vabysmo ⓘ |
| indication |
treatment of diabetic macular edema
ⓘ
treatment of neovascular (wet) age-related macular degeneration ⓘ |
| legalStatus | prescription-only medicine ⓘ |
| mechanismOfAction |
dual inhibition of VEGF-A and Ang-2 pathways
ⓘ
reduces vascular permeability in the retina ⓘ stabilizes retinal blood vessels ⓘ |
| molecularType | humanized IgG monoclonal antibody ⓘ |
| routeOfAdministration | intravitreal injection ⓘ |
| targetOrgan |
choroid
ⓘ
retina ⓘ |
| targets |
Ang-2
ⓘ
VEGF-A ⓘ angiopoietin-2 ⓘ vascular endothelial growth factor A ⓘ |
| therapeuticArea |
ophthalmology
ⓘ
retinal diseases ⓘ |
| usedFor |
diabetic macular edema
ⓘ
macular edema secondary to retinal vein occlusion ⓘ neovascular age-related macular degeneration ⓘ wet age-related macular degeneration ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: faricimab Description of subject: Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.